NVS GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Novartis AG
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Did you know?
Profit margin of 23.9% — that's well above average.
Current Price
$146.57
-0.87%GoodMoat Value
$194.53
32.7% undervaluedProfile
Valuation (TTM)
Market Cap$279.68B
P/E20.66
EV—
P/B6.06
Shares Out1.91B
P/Sales4.94
Revenue$56.58B
EV/EBITDA11.41
Novartis AG (NVS) Quality Analysis
NVS Profitability
Profitability trend analysis coming soon
NVS Growth
Growth trend analysis coming soon
NVS Financial Health
Financial health indicators coming soon
NVS Quality & Fundamental Analysis
Novartis AG (NVS) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. This quality analysis page evaluates Novartis AG's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Novartis AG has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 23.92% and a return on equity (ROE) of 29.34%. Return on assets (ROA) stands at 12.20%.
The debt-to-equity ratio is 0.77, with a current ratio of 1.12. Operating margin is 31.13%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Novartis AG is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.